Showing results (491-500 of 502) with videos related to

Sort By:
Pageof 51
JAMA|June 1, 2026
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical TrialJamie E Chaft, Zhuoxin Sun, Charles M Rudin, et al.
The Journal of Molecular Diagnostics : JMD|January 24, 2016
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal MalignanciesKevin E Fisher, Linsheng Zhang, Jason Wang, et al.
The Lancet. Oncology|February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialNaiyer A Rizvi, Julien Mazières, David Planchard, et al.
The New England Journal of Medicine|October 20, 2023
Tarlatamab for Patients with Previously Treated Small-Cell Lung CancerMyung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
Lancet (London, England)|February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trialAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Clinical Lung Cancer|August 9, 2024
Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 InfectionsMedha Somisetty, Philip C Mack, Chih-Yuan Hsu, et al.
Nature|September 28, 2022
PD-1 combination therapy with IL-2 modifies CD8<sup>+</sup> T cell exhaustion programMasao Hashimoto, Koichi Araki, Maria A Cardenas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerA Passaro, N Leighl, F Blackhall, et al.
The New England Journal of Medicine|September 21, 2020
KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2021
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialLuis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.
Pageof 51